Résumé
Prostate cancer is one of the most common male malignancies all over the world. Patients with metastatic prostate cancer (mPCa) have a poor prognosis compared to those with local disease. In China, most newly diagnosed patients are initially found with distant metastasis. Novel hormone therapies (NHT) develop rapidly in recent years. The randomized clinical trials have demonstrated significant benefits in prolonging overall survival and improving the quality of life. It is essential to choose and optimize regimens following the development of NHT. The article focuses on reviewing current and developing strategies, treatment selection, sequence, and combination in mPCa.
Résumé
Several phase Ⅲ clinical trials have confirmed that androgen deprivation therapy combined with novel hormone therapy can prolong the survival of patients with metastatic prostate cancer. It has become a commonly used scheme in clinical practice. The physical condition, concomitant diseases and economic status of patients, side effects, accessibility, costs and approved indications of drugs should also be considered when selecting the novel hormone therapy drugs for these patients. The sequential use of novel hormone therapy drugs and the conversion of corticosteroids benefit some patients, which can be selected carefully.